Two Sigma Investments LP Has $329,000 Stock Holdings in Enliven Therapeutics, Inc. (NASDAQ:ELVN)

Two Sigma Investments LP trimmed its stake in Enliven Therapeutics, Inc. (NASDAQ:ELVN) by 33.8% in the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 14,620 shares of the company’s stock after selling 7,460 shares during the quarter. Two Sigma Investments LP’s holdings in Enliven Therapeutics were worth $329,000 as of its most recent SEC filing.

A number of other large investors have also bought and sold shares of ELVN. Charles Schwab Investment Management Inc. grew its holdings in Enliven Therapeutics by 2.6% in the fourth quarter. Charles Schwab Investment Management Inc. now owns 261,888 shares of the company’s stock worth $5,892,000 after purchasing an additional 6,611 shares during the period. Swiss National Bank lifted its position in shares of Enliven Therapeutics by 13.9% during the fourth quarter. Swiss National Bank now owns 41,873 shares of the company’s stock valued at $942,000 after purchasing an additional 5,100 shares in the last quarter. Intech Investment Management LLC bought a new position in shares of Enliven Therapeutics during the fourth quarter valued at about $367,000. KLP Kapitalforvaltning AS bought a new position in shares of Enliven Therapeutics during the fourth quarter valued at about $97,000. Finally, Vanguard Group Inc. lifted its position in shares of Enliven Therapeutics by 2.9% during the fourth quarter. Vanguard Group Inc. now owns 1,975,655 shares of the company’s stock valued at $44,452,000 after purchasing an additional 55,283 shares in the last quarter. 95.08% of the stock is currently owned by institutional investors and hedge funds.

Insider Buying and Selling at Enliven Therapeutics

In other Enliven Therapeutics news, CFO Benjamin Hohl sold 3,250 shares of the stock in a transaction that occurred on Thursday, March 27th. The shares were sold at an average price of $21.33, for a total transaction of $69,322.50. Following the completion of the sale, the chief financial officer now directly owns 23,000 shares of the company’s stock, valued at $490,590. This trade represents a 12.38% decrease in their position. The sale was disclosed in a filing with the SEC, which is available through the SEC website. Also, CEO Samuel Kintz sold 12,500 shares of the firm’s stock in a transaction on Monday, March 17th. The shares were sold at an average price of $20.83, for a total transaction of $260,375.00. Following the completion of the transaction, the chief executive officer now directly owns 990,392 shares of the company’s stock, valued at approximately $20,629,865.36. This trade represents a 1.25% decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 94,444 shares of company stock worth $1,801,057. Company insiders own 25.90% of the company’s stock.

Analysts Set New Price Targets

A number of research firms recently weighed in on ELVN. HC Wainwright raised their price target on shares of Enliven Therapeutics from $39.00 to $40.00 and gave the company a “buy” rating in a research report on Thursday, May 15th. Jones Trading dropped their price target on shares of Enliven Therapeutics from $36.00 to $27.00 and set a “buy” rating on the stock in a research report on Friday, May 16th. Four research analysts have rated the stock with a buy rating and one has given a strong buy rating to the company. Based on data from MarketBeat.com, Enliven Therapeutics currently has an average rating of “Buy” and a consensus price target of $37.25.

Enliven Therapeutics Stock Up 6.7%

NASDAQ:ELVN opened at $21.70 on Wednesday. The company has a fifty day moving average of $18.09 and a 200 day moving average of $20.72. Enliven Therapeutics, Inc. has a 52 week low of $13.30 and a 52 week high of $30.03. The firm has a market capitalization of $1.06 billion, a P/E ratio of -11.42 and a beta of 0.79.

Enliven Therapeutics (NASDAQ:ELVN) last released its earnings results on Wednesday, May 14th. The company reported ($0.57) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.51) by ($0.06). As a group, analysts anticipate that Enliven Therapeutics, Inc. will post -1.95 EPS for the current year.

Enliven Therapeutics Profile

Enliven Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the discovery and development of small molecule inhibitors to help patients with cancer. The company’s lead product candidates comprise ELVN-001, which is being evaluated in a Phase 1 clinical trial in adults with chronic myeloid leukemia; and ELVN-002, a Phase 1 clinical trial in adults with solid tumors with HER2 alterations.